alexa Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.

Kidney Disorders and Clinical Practices

Author(s): Dusilova Sulkova S, Horacek J, Safranek R, Gorun P, Viklicky O,

Abstract Share this page

Abstract Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose because of hypocalcemia. We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab doses. This article was published in Acta Medica (Hradec Kralove) and referenced in Kidney Disorders and Clinical Practices

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version